CrossBody Platform

A New Era for Multispecific
Unleashing the Future of Therapeutic Antibodies

Unique Mechanism of Action (MOA)

CrossBody platform constructs multi-specific antibodies with innovative fragment, featuring a unique mechanism of action (MOA), and making undruggable targets druggable

Modulating T Cell Binding to Mitigate CRS Risk

CrossBody technology offers exceptional flexibility in efficiently modulating both tumor and T cell binding (not affinity maturation) while retaining potent efficacy in tumor cells

TAA Concealment Strategy to Minimize On-target, Off-tumor Toxicity

The flexibility of CrossBody format enables the design of multi-specific antibodies with TAA concealment (not masked or caged), improving efficacy while reducing target-mediated toxicity in normal cells